For the active substances 1,4-dimethylnaphthalene, bentazone, bixafen, fluxapyroxad, halauxifen-methyl, mecoprop-P, penthiopyrad, propyzamide, sedaxane and sulfoxaflor, as the risk assessment has not yet been finalised by the respective rapporteur Member States and in light of the remaining steps to be completed in each renewal procedure, the duration of the extension of the approval periods should be set at 29 months.
Recital 41, Regulation (EU) 2025/787
In forcesince 24 Apr 2025